Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb’s cancer cell therapies, and vaccines from France’s Sanofi.
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb’s cancer cell therapies, and vaccines from France’s Sanofi at the start of 2025, according to data analyzed by healthcare research firm 3 Axis Advisors.